Showing results (61-70 of 68) with videos related to
Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
The Lancet. Haematology|May 2, 2026
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trialM Lia Palomba, Manish R Patel, Toby A Eyre, et al.The New England Journal of Medicine|January 5, 2022
Eltrombopag Added to Immunosuppression in Severe Aplastic AnemiaRégis Peffault de Latour, Austin Kulasekararaj, Simona Iacobelli, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R Mato, Lindsey E Roeker, Ryan Jacobs, et al.Blood|July 21, 2020
Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R Mato, Lindsey E Roeker, Nicole Lamanna, et al.Leukemia|July 11, 2020
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL CampusLydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, et al.Journal of Hematology & Oncology|August 26, 2022
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLLDarko Antic, Natasa Milic, Thomas Chatzikonstantinou, et al.Leukemia|November 2, 2021
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL studyThomas Chatzikonstantinou, Anargyros Kapetanakis, Lydia Scarfò, et al.American Journal of Hematology|September 29, 2023
The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLLAndrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.Pageof 7